KRYSTAL BIOTECH INC (KRYS)
US5011471027 - Common Stock
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced...
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today...
Oversold Conditions For Krystal Biotech (KRYS)
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model...
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today...
Noteworthy Monday Option Activity: KRYS, ITRI, WING
Monday Sector Leaders: Biotechnology, Education & Training Services
Krystal Biotech GAAP EPS of $0.30 beats by $0.69, revenue of $42.1M beats by $12.17M (NASDAQ:KRYS)
Krystal Biotech beats expectations with Q4 earnings, reporting a GAAP EPS of $0.30 and revenue of $42.1M.
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report...
Krystal Biotech, Candel, Edgewise gain on FDA fast track tags (NASDAQ:KRYS)
Krystal Biotech (KRYS), Candel Therapeutics (CADL), and Edgewise Therapeutics (EWTX) are among latest to win fast-track designations from the U.S. FDA. Read more here.
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal...
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform...
Commit To Buy Krystal Biotech At $95, Earn 30.5% Annualized Using Options
Investors growing more bullish on SMID cap biotech stocks (NASDAQ:ALNY)
Investors are more bullish about small and mid-cap biotech stocks this year, with Merus (MRUS) and Fusion (FUSN) viewed as most likely to outperform, according to TD Cowen.
Krystal Biotech stock in Evercore’s Tactical Outperform list
Evercore ISI has added Krystal Biotech (KRYS) to its Tactical Outperform list citing the market rollout of its rare disease therapy Vyjuvek. Read more here.
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today...
Notable Monday Option Activity: AXP, KRYS, SNOW
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on...
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on...
Notable Thursday Option Activity: LLY, HES, KRYS
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first timeVYJUVEK...
Goldman starts Krystal Biotech at buy, cites Vyjuvek launch (KRYS)
Goldman Sachs initiated coverage of Krystal Biotech with a buy rating, citing the strong launch of Vyjuvek for a rare skin disease. Read more here.
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Have investors already missed the boat with this stock?
Top 10 earnings per share upside surprises of Q3
The article discusses the top 10 stocks that have received the largest earnings per share (EPS) upside surprises during the third quarter of 2023. Learn more.
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on...